Alix Arnaud, Director of Health Economic and Value Assessment BP at Sanofi, discusses the cost of efanesoctocog alfa compared with other Factor VIII replacement therapies for major surgeries in patients with hemophilia A.
Hemophilia A is an inherited bleeding disorder in which the blood does not clot normally. People with hemophilia A will bleed more than normal after an injury, surgery, or dental procedure. Bleeding into the joints, muscles, brain, or organs can cause pain and other serious complications. Hemophilia A is caused by having low levels of a protein called factor VIII, necessary for forming blood clots. The disorder is caused by changes in the F8 gene.
The objective of this analysis was to compare factor consumption and costs associated with major surgeries using four different Factor VIII (FVIII) replacement therapies—octocog alfa, rurioctocog alfa pegol, efmoroctocog alfa, and efanesoctocog alfa. Data were gathered from U.S. prescribing information and Phase 3 clinical trials, with 2024 wholesale acquisition costs (WAC) used for cost estimations.
For octocog alfa, rurioctocog alfa pegol, and efmoroctocog alfa, achieving pre-operative FVIII targets required administration every 8–24 hours, continuing for at least seven days post-surgery. In contrast, efanesoctocog alfa required a single pre-operative loading dose of 50 IU/kg, followed by maintenance doses every 2–3 days.
Results
Median factor consumption per major surgery varied significantly, with median values of 910 IU/kg for octocog alfa, 629 IU/kg for rurioctocog alfa pegol, 493 IU/kg for efmoroctocog alfa, and only 163 IU/kg for efanesoctocog alfa. Corresponding costs followed the same trend, with efanesoctocog alfa demonstrating the lowest perioperative cost at $78,165, compared to $157,339 for octocog alfa, $142,525 for rurioctocog alfa pegol, and $115,747 for efmoroctocog alfa.
Efanesoctocog alfa showed substantial cost savings and reduced factor consumption, using 5.5 times fewer IU than octocog alfa and saving $79,174. Compared to rurioctocog alfa pegol, it used 3.9 times less factor and saved $64,360, while against efmoroctocog alfa, it used three times less factor and saved $37,581.
These findings highlight the potential efficiency of efanesoctocog alfa in reducing both treatment burden and costs for patients with hemophilia A undergoing major surgeries.
To learn more, click here.
For more information on hemophilia and other rare hematologic conditions, visit https://checkrare.com/diseases/hematologic-disorders/